Maxim Group cuts BioRestorative Therapies to hold from buy
BRTX•Maxim Group cut its rating on BioRestorative Therapies to hold from buy.
Related News
MetLife: UBS raises target price to $110 from $105
MET•
Voya Financial: UBS raises target price to $127 from $125
VOYA•
HeartSciences wins FDA 510(k) clearance for MyoVista wavECG device
HSCS•
American International Group: UBS raises target price to $100 from $98
AIG•
Nasdaq trading halt continues; reason unavailable at 8:33 a.m.
SLP•